Non-invasive Prenatal Testing Market to Surpass USD 9.11 Bn by 2031

Global Non-invasive Prenatal Testing(NIPT) Market, by Test Type (Panel 1 Test, Panel 2 Test, and Panel 3 Test), by Application (Trisomy, Microdeletion Syndrome, Sex chromosomes abnormalities, and Others), by End User (Hospitals, Diagnostic Laboratories, and Maternity Centers), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) is estimated to be valued at US$ 4.60 Bn in 2024 and is expected to exhibit a CAGR of 10.2% during the forecast period (2024-2031), as highlighted in a new report published by Coherent Market Insights.

The increasing adoption of inorganic growth strategies such as partnership, collaboration and agreements by the key players in the market is expected to drive the market growth over the forecast period. For instance, in December 2019, Cindy Cisneros, committee for economic development, in collaboration with F. Hoffmann-La Roche Ltd, a diagnostic and technology company dedicated to offer automated solutions in non-invasive prenatal testing, completed a clinical trial study in development of non-invasive prenatal test which can be used in detection of fetal aneuploidy. Maternal blood was collected to study and identify the aneuploidy birth defects of fetus.

Global Non-invasive prenatal testing (NIPT) Market– Impact of Coronavirus (COVID-19) Pandemic

The COVID-19 pandemic and lockdowns in various countries across the globe have impacted the financial status of businesses across all sectors, including the private healthcare sector. The COVID-19 pandemic has impacted the entire supply chain of the healthcare industry, mainly due to strict lockdown in several regions. Private healthcare is one such sector that has been impacted significantly by the COVID-19 pandemic.

However, the COVID-19 pandemic had a negative impact on the non-invasive prenatal testing (NIPT) market, owing to the risk for pregnant women of transmitting infections to the fetus. For instance, in October 2021, a paper was published by National Center for Biotechnology Information according to which pregnant women are in at-risk category with unknown consequences for both fetal and pregnant women. COVID-19 pandemic had caused a significant decrease in the number of invasive procedures for prenatal diagnosis, such as chorionic villous sampling (CVS) and amniocentesis.

Global Non-invasive prenatal testing (NIPT) Market: Key Developments

In August 2019, Natera, Inc. a global leader in cell-free DNA test, announced that Panorama, a non-invasive prenatal tests (NIPT), has now more than two million processing tests and each day 2000 Panorama are processed. Panorama test has validated in 18 peer-reviewed published clinical trials. Panorama test uses a unique single-nucleotide polymorphism (SNP) based technology to analyze fetal or placental DNA obtained from blood drawn from mother.

In June 2021, Illumina, Inc., a provider of an innovative technologies, in collaboration with Next Generation Genomic Co., Ltd. (NGG Thailand), the Association of Southeast Asian Nations (ASEAN) leaders in laboratory services and reproductive science, announced the launch of VeriSeq NIPT solution v2 in Thailand. VeriSeq NIPT solution v2 is a next generation sequencing based approach to noninvasive prenatal testing (NIPT).

Browse 35 Market Data Tables and 32 Figures spread through 165 Pages and in-depth TOC on “Global Non-invasive prenatal testing (NIPT) Market”- Forecast to 2030, Global Non-invasive Prenatal Testing (NIPT) Market, by Test Type (Panel 1 Test, Panel 2 Test, and Panel 3 Test), by Application (Trisomy, Microdeletion syndrome, Syndrome, Sex Chromosomes Abnormalities, and Others),  by End User (Hospitals, Diagnostic Laboratories, and Maternity Centers), and by Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa)

To know the latest trends and insights prevalent in this market, click the link below:

https://www.coherentmarketinsights.com/market-insight/non-invasive-prenatal-testing-nipt-market-579

Moreover, increasing prevalence of chromosomal abnormalities is expected to drive the market growth over the forecast period. For instance, in May 2021, a study was conducted in Al-Madinah Al-Munawarah (MMCH), a hospital for medical care of pregnant women, in the capital of Medina, on newborns aged from one to 28 days with major congenital abnormalities and admitted to neonatal intensive care unit. Out of 13,988 live births delivered in maternity and children hospital, total admission in Neonatal Intensive Care Unit (NICU) were 2,541, out of which congenital abnormalities were detected in 150 newborns. Thus, congenital abnormalities are leading causes of neonatal death and childhood disabilities.

Key Takeaways of the Global Non-invasive prenatal testing (NIPT) Market:

• The global non-invasive prenatal testing (NIPT) market is expected to exhibit a CAGR of 10.2% during the forecast period owing to increasing awareness about the adoption of non-invasive prenatal testing. For instance, in March 2019, Yourgene Health Plc, an international molecular diagnostics group, arranged an event in Egypt to increase the awareness of IONA test, a non-invasive prenatal DNA test performed for Down syndrome.
• Among application, sex chromosomes abnormalities segment is estimated to hold a dominant position in the global non-invasive prenatal testing (NIPT) market over the forecast period, owing to the most common causes of miscarriages, perinatal mortality, and others. For instance, a paper was published by National Center for Biotechnology Information in January 2021, according to which the fetal aneuploidies one of the type of sex chromosome abnormalities are the most common reason behind neurodevelopmental impairments, perinatal mortality and miscarriages.
• Among region, North America is estimated to account for the largest market share in the global non-invasive prenatal testing (NIPT) market over the forecast period, due to the increasing adoption of inorganic strategies such as collaborations and partnerships by the key players operating in the U.S. for carrying out research activities on non-invasive prenatal tests. For instance, in March 2021, Illumina Inc., a biotechnology company, along with the researchers of Harvard Pilgrim Health Care(HPHC) and University of Colorado reports study results which evaluate the impact of risk share agreement of Non-invasive prenatal tests(NIPT) that opened an insurance coverage for pregnant women under the age of 35. Under this agreement, around thousands of women obtained access to NIPT and the economic impact was less
• Major players operating in the global non-invasive prenatal testing (NIPT) market include F. Hoffmann-La Roche Ltd, BGI Group, Berry Genomics Co., Ltd., Illumina, Inc., Eurofin Scientific, Natera, Inc., Sequenom, Inc., Axia Women’s Health , Eluthia, BillionToOne, Inc., Quest Diagnostics Incorporation., Igenomix, Agilent Technologies, Inc., Laboratory Corporation of America Holdings., PerkinElmer, Inc., ThermoFisher Scientific, Yourgene Health PLC